Search Videos and More
Video
ASCO26: Toni Choueiri, MD, KEYNOTE-654
Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.
Video
ASCO26: Alicia Morgans, MD, MPH, ARACOG
Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.
Video
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101
A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.
Video
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04
Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.
Video
2026 ASCO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.
Video
2026 ASCO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates
Video
ASCO26: Michael Hassett, MD, MPH, eSyM
Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.
Video
ESMO Breast Cancer 2026 Highlights: SERENA-6
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the SERENA-6 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights: TRAK-ER
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights: Saci-IO HR+
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights Panel Discussion
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.